Trials / Completed
CompletedNCT00179660
Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)
A Phase II, Multicenter, Single-Arm, Open-Label Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide (Revlimid®, CC-5013) In Subjects With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Celgene Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the activity of lenalidomide in relapsed or refractory aggressive NHL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenalidomide | Capsules for oral administration. |
Timeline
- Start date
- 2005-08-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2005-09-16
- Last updated
- 2016-01-21
- Results posted
- 2013-09-02
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00179660. Inclusion in this directory is not an endorsement.